Dana Abendschein Email & Phone Number

Experienced Adjunct Professor at St. Louis University with a demonstrated history of working as a collaborator on cross-disciplinary research at Washington University School of Medicine (37years) two years in the primary role as Director of Research for Euphrates Vascular/Pulse Therapeutics, Inc. to advance new technology to treat ischemic stroke and myocardial infarction. Now a CV preclinical consultant and study manager. Previously, tenured Associate Professor at Washington University School of Medicine and teaching faculty for first year cardiac physiology and Course Director for Pathophysiology and Pharmacology in second year at Wash U for 20 and 15 years, respectively. Skilled in basic and applied preclinical research, animal modeling of cardiovascular disease, physiology and pharmacology, and development of novel approaches to treat and inhibit thrombosis based on physiologic and vascular defense mechanisms (PhD in BioEng and Vet Med, Purdue) with minimal bleeding side-effects. Strong education professional with post-doctoral training focused on Cardiopulmonary Physiology, early detection of MI by CK isoform analysis, and cardiac performance in animal models with Eliot Rapaport at University of California, San Francisco (CVRI). Worked on initial optimization and adjunctive therapeutics for use with rtPA fibrinolysis with Burt Sobel at WU. Most recently studied increased efficacy of lytics for treatment of stroke and MI using iron oxide MicroBeads injected near lodge blood clot and a magnet to move lytics into occluded vessels for accelerated recanalization during stroke and MI. Continuing development of antithrombotics with start-ups based on optimized physiomimetic antiplatelet/anticoagulant proteins that do not cause bleeding or prolonged anticoagulation.

Listed skills include Research, Science, Teaching, Higher Education, and 13 others.